Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
McKesson Corporation reported its fiscal fourth-quarter 2025 earnings with revenue of $90.82 billion, which fell short of the estimated $94.30 billion but represented a 19% increase year-over-year. Adjusted earnings per share (EPS) came in at $10.12, surpassing the estimate of $9.82 and reflecting a 64% increase. Adjusted net income was $1.27 billion, also above the $1.23 billion estimate. Reported EPS stood at $10.01, up $3.99 from the previous year. The company cited strong performance driven by U.S. pharmaceutical growth and specialty oncology volumes. For fiscal year 2026, McKesson provided an adjusted EPS outlook ranging from $36.75 to $37.55, slightly above analyst expectations. Additionally, McKesson announced plans to separate its Medical-Surgical Solutions segment to unlock further value.
McKesson Corporation, $MCK, Q4-FY25. Results: 📊 Adj. EPS: $10.12 🟢 💰 Revenue: $90.8B 🔴 🔎 Strong Q4 driven by U.S. Pharma growth and specialty oncology volumes; company plans to spin off Medical-Surgical Solutions segment to unlock further value.
$MCK Earnings: - Consolidated revenues of $90.8 billion increased 19%. - Earnings per diluted share of $10.01 increased $3.99. - Adjusted Earnings per Diluted Share of $10.12 increased 64%. "McKesson delivered strong fourth quarter performance reporting revenue growth of 19% https://t.co/9FYjgEYTmt
$MCHP | Microchip Q4 25 Earnings • Adj. EPS: $0.11 (est. $0.10) • Net Sales: $970.5M (est. $962.7M) • Sees Q1 Adj. EPS Guidance: $0.18–$0.26 (est. $0.16) • Sees Q1 Net Sales Guidance: $1.02B–$1.07B (est. $983.5M) • Quarterly Dividend: $0.455 per share (unchanged)
